Immutep Beheer

Beheer criteriumcontroles 3/4

De CEO Immutep is Marc Voigt, benoemd in Nov2012, heeft een ambtstermijn van 10.33 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 1.06M, bestaande uit 44.8% salaris en 55.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.78% van de aandelen van het bedrijf, ter waarde € 2.15M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.9 jaar en 2.5 jaar.

Belangrijke informatie

Marc Voigt

Algemeen directeur

AU$1.1m

Totale compensatie

Percentage CEO-salaris	44.8%
Dienstverband CEO	12yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	6.9yrs
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Marc Voigt's beloning veranderd ten opzichte van Immutep's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$1m	AU$477k	-AU$43m
Mar 31 2024	n/a	n/a	-AU$42m
Dec 31 2023	n/a	n/a	-AU$41m
Sep 30 2023	n/a	n/a	-AU$40m
Jun 30 2023	AU$1m	AU$440k	-AU$40m
Mar 31 2023	n/a	n/a	-AU$38m
Dec 31 2022	n/a	n/a	-AU$37m
Sep 30 2022	n/a	n/a	-AU$34m
Jun 30 2022	AU$943k	AU$428k	-AU$32m
Mar 31 2022	n/a	n/a	-AU$29m
Dec 31 2021	n/a	n/a	-AU$26m
Sep 30 2021	n/a	n/a	-AU$28m
Jun 30 2021	AU$995k	AU$409k	-AU$30m
Mar 31 2021	n/a	n/a	-AU$29m
Dec 31 2020	n/a	n/a	-AU$27m
Sep 30 2020	n/a	n/a	-AU$20m
Jun 30 2020	AU$926k	AU$411k	-AU$13m
Mar 31 2020	n/a	n/a	-AU$15m
Dec 31 2019	n/a	n/a	-AU$16m
Sep 30 2019	n/a	n/a	-AU$17m
Jun 30 2019	AU$837k	AU$399k	-AU$18m
Mar 31 2019	n/a	n/a	-AU$18m
Dec 31 2018	n/a	n/a	-AU$17m
Sep 30 2018	n/a	n/a	-AU$15m
Jun 30 2018	AU$1m	AU$401k	-AU$13m

Compensatie versus markt: De totale vergoeding ($USD 691.88K ) Marc } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 846.96K ).

Compensatie versus inkomsten: De vergoeding van Marc is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Marc Voigt (51 yo)

12yrs

Tenure

AU$1,064,669

Compensatie

Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Marc Voigt	CEO, MD	12yrs	AU$1.06m	0.78% € 2.1m
Deanne Miller	COO, General Counsel & Joint Company Secretary	12.1yrs	AU$565.23k	0.18% € 507.7k
Frederic Triebel	Chief Scientific Officer & Executive Director	9.9yrs	AU$864.44k	0.61% € 1.7m
Florian Vogl	Chief Medical Officer	1.5yrs	AU$955.82k	geen gegevens
Christian Mueller	Senior Vice President of Regulatory & Strategy	1.1yrs	geen gegevens	geen gegevens
Indira Naidu	Joint Company Secretary	3.8yrs	geen gegevens	geen gegevens

6.9yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van YP1B is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Marc Voigt	CEO, MD	10.3yrs	AU$1.06m	0.78% € 2.1m
Frederic Triebel	Chief Scientific Officer & Executive Director	2.2yrs	AU$864.44k	0.61% € 1.7m
Russell Howard	Independent Non-Executive Chairman	11.5yrs	AU$163.52k	0.077% € 211.9k
Pete Meyers	Independent Non-Executive Deputy Chairman	10.8yrs	AU$138.71k	0.25% € 697.3k
Martine Piccart	Chairman of Clinical Advisory Board	7.4yrs	geen gegevens	geen gegevens
Scott Antonia	Member of Clinical Advisory Board	2.5yrs	geen gegevens	geen gegevens
Leisha Emens	Member of Clinical Advisory Board	2.5yrs	geen gegevens	geen gegevens
Elisabeth Boyce	Non-Executive Director	1.6yrs	AU$144.76k	geen gegevens
Salah-Eddin Al-Batran	Member of Clinical Advisory Board	7.4yrs	geen gegevens	geen gegevens
Martin Forster	Member of Clinical Advisory Board	2.5yrs	geen gegevens	geen gegevens
Hans Wildiers	Member of Clinical Advisory Board	2.5yrs	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van YP1B wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

Immutep Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Limited, Annual General Meeting, Oct 24, 2023

Less than half of directors are independent

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Appoints Frederic Triebel as Executive Director

Recent updates

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.045 loss in FY 2023)

No longer forecast to breakeven

Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress

Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression

New minor risk - Shareholder dilution

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

No longer forecast to breakeven

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep Limited, Annual General Meeting, Oct 24, 2023

Full year 2023 earnings released: AU$0.045 loss per share (vs AU$0.038 loss in FY 2022)

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Forecast to breakeven in 2026

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

No longer forecast to breakeven

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Less than half of directors are independent

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

No longer forecast to breakeven

Full year 2022 earnings released: AU$0.038 loss per share (vs AU$0.05 loss in FY 2021)

Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022

Forecast to breakeven in 2025

Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

High number of new and inexperienced directors

Immutep Limited Announces Executive Changes

Immutep Limited Presents New and Significant Data from the AIPAC Study

Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022

Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients

Immutep Limited Announces New Interim Data in 2nd Line Metastatic NSCLC from Its Phase II TACTI-002 Trial

High number of new directors

First half 2022 earnings: EPS in line with expectations, revenues disappoint